These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7555407)

  • 1. [The clinical study of local treatment of ocular malignant tumors with IL-2 LAK cells].
    Yang L; Zhang J; Liang G
    Zhonghua Yan Ke Za Zhi; 1995 May; 31(3):215-7. PubMed ID: 7555407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The observation on treatment effects of local adoptive immunotherapy in 33 cases with head and neck cancer].
    Han D; Zhu X; Huang Z
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):454-6. PubMed ID: 10920882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical observation of immunotherapy in ocular malignant tumors with lymphokine-activated killing (LAK) cell].
    Yang L; Wang H; Zhang X; Zhang J; Liang G
    Yan Ke Xue Bao; 1993 Jun; 9(2):51-4. PubMed ID: 8276089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Locoregional adoptive immunotherapy using LAK cells and IL-2 against liver metastases from digestive tract cancer].
    Ueda Y; Sonoyama T; Itoi H; Fujiwara H; Fuji N; Itoh T; Fujiki H; Yamashita T; Yoshimura T; Harada S; Okugawa K; Yamagishi H
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1962-5. PubMed ID: 11086454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
    Cao GW; Yang WG; Du P
    Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):428-31. PubMed ID: 7720497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adoptive immunotherapy in patients with medulloblastoma by LAK cells].
    Shimizu K; Tamura K; Yamada M; Okamoto Y; Miyao Y; Park K; Matsui Y; Hayakawa T; Takimoto H; Mogami H
    No To Shinkei; 1989 Oct; 41(10):991-5. PubMed ID: 2605046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [LAK cells and cancer].
    Taguchi T; Kimoto Y
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new approach to the treatment of malignant effusion.
    Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
    Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
    Basse PH
    APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
    Liu X
    Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of advanced liver cancer by autologous and/or homologous LAK cells combined with human natural LL-2].
    Han FG
    Zhonghua Zhong Liu Za Zhi; 1991 Mar; 13(2):145-8. PubMed ID: 1879294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
    Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
    Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
    Mao G; Gao Z; Wang Q
    Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.